What do “drug substance” and “drug product” mean (and how a CDMO fits in)?
“Drug substance” is the active pharmaceutical ingredient (API) or bulk intermediate that provides the therapeutic effect. “Drug product” is the final, formulated dosage form (for example, tablets, capsules, injections) made from the drug substance, plus necessary excipients and packaging under defined quality controls.
A CDMO (contract development and manufacturing organization) can support one or both steps:
- Drug substance manufacturing (upstream and/or API process development, synthesis, purification, and bulk release).
- Drug product manufacturing (formulation development, filling/finishing, packaging, and final batch release).
What services do CDMOs typically offer for drug substance vs drug product?
For drug substance, CDMOs commonly handle:
- Process development and scale-up for the API or key intermediates
- GMP manufacture of clinical or commercial API (batch records, in-process controls, impurity control)
- Analytical testing tied to release specs (identity, assay, impurities, residual solvents, etc.)
For drug product, CDMOs commonly handle:
- Formulation development (choosing excipients, dose form, stability-relevant decisions)
- GMP manufacturing of finished dosage forms (mixing, granulation, lyophilization, sterile manufacturing, fill/finish)
- Quality and release testing for the finished product (content uniformity, dissolution, sterility/endotoxin where relevant)
When would a project need both drug substance and drug product from the same CDMO?
Companies often choose a single CDMO for both if they want tighter coordination across the API-to-finished-product handoff:
- Faster tech transfer from API quality attributes to finished product performance
- Fewer compatibility issues (for example, how API particle properties or impurity profiles affect formulation, dissolution, or stability)
- Streamlined project management for clinical and commercial timelines
That said, some sponsors split work across different suppliers to match specialized capabilities (for example, one CDMO for sterile fill/finish and another for API).
What’s the practical difference in regulatory expectations between drug substance and drug product?
In regulatory submissions, drug substance and drug product are treated as distinct quality objects:
- Drug substance controls focus on API properties, impurities, residuals, and the ability to consistently manufacture it to spec.
- Drug product controls focus on dosage form characteristics and performance (for example, dissolution or sterility/endotoxin for injectables), plus stability.
Both must be manufactured under GMP with documentation that supports the overall quality system and lifecycle expectations.
How do CDMOs manage handoff: from API quality attributes to the finished dosage form?
CDMOs typically manage the “bridge” between drug substance and drug product through:
- Defining which API attributes matter to finished product performance (often called critical quality attributes)
- Using development batches to map relationships between API characteristics and finished product outcomes
- Setting change controls and ongoing testing plans so changes to the API process do not unexpectedly affect the drug product
What does “CDMO for drug substance and drug product” usually include in a contract?
Common contract elements include:
- Scope of work by phase (process development, clinical GMP batches, commercial scale, stability)
- Quality agreement requirements (testing responsibilities, specifications, release timelines)
- Support for regulatory filings (CTD modules, validation packages, tech transfer documentation)
- Timelines for tech transfer, batch schedules, deviations/CAPA handling, and change management
Key risks customers watch when selecting a CDMO (drug substance vs drug product)
Drug substance risks often relate to achieving consistent API quality at the intended scale, managing impurities, and controlling residual solvents/byproducts.
Drug product risks often relate to formulation robustness, process reproducibility, and for sterile products, contamination control and validated aseptic processes.
If you meant “drug substance vs drug product” for labeling or specs: what exactly changes?
What changes between drug substance and drug product is the testing and acceptance criteria. Drug substance specs are tied to the API’s chemical quality. Drug product specs are tied to how the final dosage form meets performance and safety expectations (for example, sterility, uniformity, dissolution).
Where can I look up specific CDMO capabilities and examples?
DrugPatentWatch.com sometimes provides industry context and references around development and manufacturing/market activity. You can search for relevant drug programs there: https://www.drugpatentwatch.com/
Sources (used)
1. https://www.drugpatentwatch.com/